Results 101 to 110 of about 1,221,411 (264)

Risk stratification for hepatitis B virus related hepatocellular carcinoma

, 2014
Hepatitis B virus (HBV) infection is the major cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC) worldwide, especially in the Asia-Pacific region.
Lin, Chih-Lin;Kao, Jia-Horng, 高嘉宏
core  

The hepatitis B virus reactivation after transarterial chemoembolization in Chinese hepatocellular carcinoma patients with low serum hepatitis B virus DNA level

Therapeutics and Clinical Risk Management, 2015
Wenbo Shao, Fengjuan Zhang, Ning Cong, Jinpeng Li, Jinlong SongDepartment of Surgical Oncology (Interventional Therapy), Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, Jinan, People’s Republic of ChinaObjective ...
Shao W, Zhang F, Cong N, Li J, Song J
doaj  

Risk Prediction of Early‐Onset Hepatocellular Carcinoma: Derivation and Validation in a Nationwide Young Adult Cohort

Alimentary Pharmacology &Therapeutics, EarlyView.
In 1,756,593 young adults, a generalized boosted survival model predicted incident HCC with strong discrimination (1‐year AUROC 0.945; 5‐year 0.825). The 1‐year horizon uniquely targets an imaging‐silent, pre‐diagnosis window, showing routine clinical signals can flag otherwise undetectable risk.
Seogsong Jeong, Gi‐Ae Kim, Heejoon Jang, Dong Hyeon Lee, Sae Kyung Joo, Keon Wook Kang, Hwamin Lee, Won Kim   +7 more
wiley   +1 more source

HBV DNA Quantitation Using Real-time PCR

Annals of Laboratory Medicine, 2006
Accurate measurement of the concentration of hepatitis B virus (HBV) DNA in clinical samples is important for the appropriate treatment of patients and evaluation of their therapeutic responses. In addition, the concentration of HBV DNA in the serum of patients with chronic HBV infection has a very broad range.
Jeong, Heo, Won Ook, Go, Gwang Ha, Kim, Dae Hwan, Kang, Geun Am, Song, Mong, Cho, Hyung Hoi, Kim, Eeu Yup, Lee   +7 more
openaire   +2 more sources

Temporal Association Between COVID‐19 Vaccination and HBsAg Loss in Chronic Hepatitis B Infection: An Interrupted Time Series Analysis

Alimentary Pharmacology &Therapeutics, EarlyView.
In 59,946 chronic hepatitis B patients followed over 23 years, COVID‐19 vaccination rollout was temporally associated with a 56% increase in HBsAg loss rates (peak 1.27 per 100 person‐years in 2022), followed by gradual waning. Negative control outcomes showed no similar pattern, supporting biological specificity. ABSTRACT Background and Aims Hepatitis
Jonggi Choi, Allison Carroll, Vy H. Nguyen, Megan Michta, Xuan Q. Zhang, Young‐Suk Lim, Raymond T. Chung   +6 more
wiley   +1 more source

Effect of HIV infection and antiretroviral therapy on hepatitis B virus (HBV)-specific T cell responses in patients who have resolved HBV infection

, 2005
Coinfection with hepatitis B virus (HBV) is a common occurrence in human immunodeficiency virus (HIV)–positive patients and an increasing cause of morbidity and mortality.
Dunn, C., Maini, M.K., Copas, A., Gilson, R.J., Lascar, R.M., Johnstone, R., Bertoletti, A., Webster, G., Lopes, A.R., Reignat, S.   +9 more
core  

Incidence of Hepatitis B Virus Reactivation in Patients Treated With Immunosuppressive and Chemotherapeutic Agents

Alimentary Pharmacology &Therapeutics, EarlyView.
HBV reactivation incidence varied across immunosuppressive and chemotherapeutic agents. Clinically meaningful HBV reactivation was also observed in patients receiving corticosteroids and conventional immunosuppressive therapies. ABSTRACT Background Data on the incidence of hepatitis B virus reactivation (HBVr) remain limited. In Japan, patients who are
Kazuhiko Ikeuchi, Makoto Saito, Kazuya Okushin, Toshiyuki Kishida, Akira Kado, Kyoji Moriya, Kazuhiko Koike, Takeya Tsutsumi, Hiroshi Yotsuyanagi   +8 more
wiley   +1 more source

Quantification of the genome equivalent of HBV virion DNA in concentrated HBV particles.

, 2015
(A) HBV virions and naked capsids in the indicated volume of virus stock were separated by native agarose gel electrophoresis, and viral DNA was detected by hybridization.
Dawei Cai (433179), Ran Yan (433180), Haitao Guo (276341), Andrea Cuconati (276334), Yuanjie Liu (203485), Yongmei Zhang (16501)   +5 more
core   +1 more source

HBV RNA at 6 months after nucleos(t)ide analogues treatment can predict antiviral efficacy in chronic hepatitis B patients

BMC Gastroenterology
Background This multicenter study evaluated serum HBV RNA as a prognostic biomarker for nucleos(t)ide analogue (NA) therapy in chronic hepatitis B (CHB), focusing on correlations with HBV DNA/HBsAg and predictive value for virological response (VR) and ...
Yandi Xie, Xiaojing Zhang, Xiaozhou Yang, Sujun Zheng, Shuyun Zhang, Xiaoying Zhang, Haiyan Kang, Xuefei Duan, Wenpin Cai, Peng Yin, Xinghuan Ma, Juan liu, Fengmin Lu, Lizhong Dai, Bo Feng   +14 more
doaj   +1 more source

Marked variation in eligibility criteria across registrational trials for relapsed diffuse large B‐cell lymphoma limits applicability to clinical practice

British Journal of Haematology, EarlyView.
Summary Therapeutic options for relapsed or refractory diffuse large B‐cell lymphoma (rDLBCL) have expanded following accelerated approvals based largely on surrogate end‐points, yet confirmatory studies have not consistently reproduced these benefits across all agents, and outcomes for many patients remain poor.
Elizabeth Goodall, Jodie Palmer, Arina Martynchyk, Niamh Waters, Fiona Swain, Tran Binh Giang, Tamara Marconi, Jamie Brennan, Gareth P. Gregory, Chan Cheah, Colm Keane, Eliza A. Hawkes   +11 more
wiley   +1 more source